Brentuximab Vedotin Approved for Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-expressing Mycosis Fungoides

Share this content:
The U.S. Food and Drug Administration has approved brentuximab vedotin for the treatment of adult patients with pcALCL or CD30-expressing mycosis fungoides who have received prior systemic therapy.
The U.S. Food and Drug Administration has approved brentuximab vedotin for the treatment of adult patients with pcALCL or CD30-expressing mycosis fungoides who have received prior systemic therapy.

The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides who have received prior systemic therapy.

The approval of brentuximab vedotin comes after the randomized, phase 3, open-label, multicenter ALCANZA trial which studied the use of brentuximab vedotin in patients with mycosis fungoides or pcALCL who had previously received one prior systemic therapy and required systemic treatment. The ALCANZA trial randomly assigned 131 patients 1:1 to receive either brentuximab vedotin or the physician's choice of either methotrexate or bexarotene.

Factors including improvement in objective response rate lasting 4 months (ORR4), complete response rate, and progression-free survival (PFS) assessed by an independent review facility were used to determine efficacy. The trial showed an improvement (P < .001) in ORR4 in the brentuximab vedotin arm compared with the physician's choice arm (56% [95% CI: 44%, 68%] vs. 12% [95% CI 4%, 21%], respectively). The brentuximab vedotin arm also experienced superior rates of complete response (P = .007) compared with the physician's choice arm, 16% (95% CI: 8%, 27%) compared with 2% (95%CI: 0, 8%). The researchers also found an improvement in PFS, the median PFS was 17 months in the brentuximab vedotin arm compared with 4 months in the physician's choice arm.

More than 20% of patients who received treatment with brentuximab vedotin experienced adverse reactions including anemia, peripheral sensory neuropathy, nausea, diarrhea, fatigue, and neutropenia. Discontinuation of therapy occurred most frequently in relation to peripheral neuropathy.

The recommended dose of brentuximab vedotin is 1.8 mg/kg up to a maximum of 180 mg as an intravenous infusion over 30 minutes every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity.

Reference

  1. FDA approves Brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma [news release]. Silver Spring, MD: US Food and Drug Adiminstration; Updated November 9, 2017. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm584543.htm. Accessed November 10, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters